• Pro Medicus nabs $24m, 7-year deal with renowned US cancer centre
  • EMvision  set to conduct device trials at three hospitals
  • EZZ surges after reporting a solid quarter

 

Pro Medicus’ big deal

Health imaging company Pro Medicus (ASX:PME) has announced a $24 million, 7-year deal with Memorial Sloan Kettering Cancer Center (MSKCC), one of the world’s most respected comprehensive cancer centres.

Under the deal, Pro Medicus will provide its cloud-engineered Visage 7 Enterprise Imaging device to be implemented throughout MSKCC.

This includes the Visage 7 Open Archive and Visage 7 Workflow modules, which provide the distribution of images to be integrated with MSKCC’s electronic health record (EHR).

Planning for the rollout is to commence immediately, with go-live targeted for Q1 of the 2024 calendar year.

MSKCC is recognised as one of the top two cancer hospitals in the US for more than 30 years.

It operates a total of 24 inpatient and outpatient locations across the New York City metropolitan region, and attracts patients from across the globe seeking premier comprehensive cancer care.

“MSKCC joins our growing list of Tier 1 academic clients and builds on our sizable presence in New York City and Long Island,” said Dr Sam Hupert, Pro Medicus CEO.

“With MSKCC’s premier reputation and global reach for research and education, an ever-increasing number of renowned physicians will be exposed to the benefits of Visage.”

 

EMvision set to conduct device trials at three hospitals

EMvision Medical Devices (ASX:EMV) said that all of its three clinical trial sites are live, with enrolment now open at Princess Alexandra Hospital, Brisbane.

Sites that have been selected are major stroke centres that treat significant volumes of stroke patients each year. They have been activated progressively, commencing with Liverpool Hospital.

Separately, an enrolment milestone has been reached under Project Agreement with the Australian Stroke Alliance (ASA), and this will trigger a further $600,000 non-dilutive milestone payment to EMV.

EMVision CEO Scott Kirkland said the company’s vision is to drive innovation in end-to-end stroke management, at the point-of-care, wherever the patient is.

“Our technology has the potential to enable earlier diagnosis in the acute phase, and aid bedside post-treatment and intervention monitoring in a manner otherwise not possible today.”

 

EZZ’s solid quarter

EZZ Life Science (ASX:EZZ) surged 13% this morning after reporting cash receipts from customers totalling $13.5 million for the quarter, up 193% on pcp and 21% on the previous quarter.

This growth was primarily driven by continued sales growth on its e-commerce distribution channels in international markets.

EZZ also generated an operating cash inflow of $2 million during the quarter, which increased significantly by $1.9 million versus the pcp.

During the quarter, EZZ released a total of four new products including one core product and three non-core products.

EZZ is ranked 41st in the Australian Financial Review’s Fast Global List, highlighting Australian companies seeing rapid growth in international revenue.

The company’s cash position remains strong at $13.8 million at the end of the quarter, and it is debt free.

 

Share prices today:

 

 

At Stockhead we tell it like it is. While EZZ Life Science is a Stockhead advertiser, it did not sponsor this article.

Read MoreBiotech

Featured Companies

You might be interested in